-$0.39 EPS Expected for Alpine Immune Sciences, Inc. (NASDAQ:ALPN) This Quarter

Equities research analysts predict that Alpine Immune Sciences, Inc. (NASDAQ:ALPNGet Rating) will announce earnings of ($0.39) per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Alpine Immune Sciences’ earnings, with the highest EPS estimate coming in at ($0.23) and the lowest estimate coming in at ($0.58). Alpine Immune Sciences posted earnings per share of ($0.46) during the same quarter last year, which would indicate a positive year over year growth rate of 15.2%. The business is expected to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Alpine Immune Sciences will report full year earnings of ($0.82) per share for the current fiscal year, with EPS estimates ranging from ($1.50) to $0.41. For the next financial year, analysts expect that the company will report earnings of ($1.63) per share, with EPS estimates ranging from ($1.94) to ($0.98). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPNGet Rating) last announced its quarterly earnings results on Thursday, May 12th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06). Alpine Immune Sciences had a negative net margin of 139.41% and a negative return on equity of 46.87%.

A number of analysts recently commented on ALPN shares. Zacks Investment Research cut Alpine Immune Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, March 22nd. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of Alpine Immune Sciences in a research report on Friday, May 13th. Wedbush reiterated an “outperform” rating and set a $22.00 price objective on shares of Alpine Immune Sciences in a research report on Tuesday, May 17th. Finally, Oppenheimer reduced their price target on Alpine Immune Sciences from $19.00 to $17.00 in a research report on Monday, March 7th.

Alpine Immune Sciences stock traded up $0.04 during mid-day trading on Tuesday, reaching $8.34. 138,779 shares of the stock traded hands, compared to its average volume of 113,061. The stock has a market capitalization of $252.94 million, a PE ratio of -4.69 and a beta of 1.74. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.58 and a quick ratio of 2.58. Alpine Immune Sciences has a 12-month low of $6.00 and a 12-month high of $14.40. The business’s 50-day moving average is $8.61 and its 200-day moving average is $9.77.

Several large investors have recently added to or reduced their stakes in the stock. Barclays PLC boosted its stake in Alpine Immune Sciences by 223.1% during the third quarter. Barclays PLC now owns 4,747 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 3,278 shares during the last quarter. Geode Capital Management LLC boosted its stake in Alpine Immune Sciences by 1.3% during the third quarter. Geode Capital Management LLC now owns 194,021 shares of the biotechnology company’s stock valued at $2,070,000 after buying an additional 2,483 shares during the last quarter. BlackRock Inc. boosted its stake in Alpine Immune Sciences by 0.7% during the third quarter. BlackRock Inc. now owns 547,782 shares of the biotechnology company’s stock valued at $5,844,000 after buying an additional 3,627 shares during the last quarter. Two Sigma Investments LP boosted its stake in Alpine Immune Sciences by 131.9% during the third quarter. Two Sigma Investments LP now owns 39,218 shares of the biotechnology company’s stock valued at $418,000 after buying an additional 22,304 shares during the last quarter. Finally, Frazier Management LLC boosted its stake in Alpine Immune Sciences by 0.7% during the fourth quarter. Frazier Management LLC now owns 1,784,913 shares of the biotechnology company’s stock valued at $24,721,000 after buying an additional 13,069 shares during the last quarter. Hedge funds and other institutional investors own 77.00% of the company’s stock.

Alpine Immune Sciences Company Profile (Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.

Read More

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.